Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
about
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancerMaximal testosterone suppression in the management of recurrent and metastatic prostate cancerApplication of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy.Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostatesA double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.Multi-parametric magnetic resonance imaging as a management decision tool.Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.SNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression.Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvateWeight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era.Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.Cigarette smoking and prostate cancer recurrence after prostatectomy.Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS.A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomyProstate cancer management: (1) an update on localised diseaseGene expression profiling identifies clinically relevant subtypes of prostate cancer.Continence rate and oncological feasibility after total transurethral resection of the prostate as an alternative therapy for the treatment of prostate cancer: a pilot study.Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate CancerFunctional imaging for prostate cancer: therapeutic implications.Changes in Prostate Cancer Aggressiveness over a 12-Year Period in Korea.Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy.An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.Low risk prostate cancer in men under age 65: the case for definitive treatment.Multiparametric magnetic resonance imaging in prostate cancer: present and futureAdvances in MR spectroscopy of the prostate.An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer.The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approachAn updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.SPOP mutations in prostate cancer across demographically diverse patient cohorts.Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactorEffectiveness and cost-effectiveness of prognostic markers in prostate cancer.The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer.Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.Is prostate cancer stage migration continuing for black men in the PSA era?Laparoscopic radical prostatectomy with bladder neck preservation: positive surgical margin and urinary continence status.Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadia
P2860
Q24299807-2C00CBBE-A2D6-4A15-8431-685A3489C6A8Q29994552-507E3B6C-9B5F-4112-B4DA-093BB542EAA1Q30911744-6E64479E-03CD-4666-850A-85021C4065FBQ33389634-01CAB04A-D5B8-4BF1-B42B-235B139206E5Q33725993-0A57D145-3CB6-4713-B7A3-0E03769C7420Q33773593-BF364766-3FE7-4078-B509-3F1E5D62486EQ33890160-F39F7E01-B356-43AD-AE8A-3003E9CCA568Q33965472-8124DC73-F640-4EE1-807B-38728542DD39Q34319619-57260C07-5811-4980-B274-F0F7C666AFD7Q34359533-09F0D94D-E114-4C8C-90E7-4E048D942B6FQ34768848-B0A7C286-B6B5-41CE-91A8-B75F9849D445Q34918676-2E8C9F81-3C1C-4848-9533-E117ACBCF560Q34988367-EFDCDC79-73A7-42C6-B8C9-6A71B80DBBBFQ35033878-98C83FCC-C964-4D0D-B55C-A2AE14E8B4FEQ35322697-ADA92765-2239-4C45-B01E-9F5B5702E03FQ35517935-282B7C51-8A6D-4142-AE57-A7EACE071D8DQ35554359-CDD871A1-C1DD-447D-AE99-4DE41F3D573AQ35667314-54C631F8-2E14-414D-9960-DA87B860945BQ36056197-22B291B0-0136-42FF-9FA5-ABB0DA8139F9Q36128629-2589AF17-4B7C-4DB3-8319-79EF0B685BF6Q36374511-1B3B14F4-0707-4B81-82E2-1E65E62D04CBQ36385264-8BF762B9-1F68-4C18-B3D6-CA889496142FQ36610246-3E0C1254-2072-4B3F-8476-256629A76A01Q37019380-45482E56-BD7F-479F-AD89-6D6863A7463EQ37036294-DABEB9B7-F244-4010-8A73-2864B4267415Q37300338-60B65A4B-342E-48B2-8E61-1BC5CB0583AEQ37337722-E529A33A-CE97-4B07-B75C-DA371D232222Q37337735-944ACF69-F618-4FE7-944B-DF6DD419FBD2Q37421914-3F8947D0-334E-41BA-9801-62C493BBA19EQ37584305-9DDC849E-8E74-4613-B945-11D933594BA1Q37686102-1D370CF5-E5F8-40E7-A007-1026CDF332C0Q38302713-5988D958-DE0F-4A5C-8C20-57BBC3D3EFE4Q38594174-4A2F2FA6-887A-4286-9F6B-4DF7609BE04DQ38657139-481D297F-28D7-4CA0-864D-A1B3E87AE9F5Q39064637-53FC4097-2039-4E96-AFC1-8DE32E13D70FQ39780124-A8B5A771-CF00-49B7-8A88-FF9EB77521BCQ40030927-6B0E214E-854A-469E-BAA1-02F276DA8198Q40377882-C29EC484-53E7-4352-8EBE-5633A828B615Q41857923-D4B0BD04-591B-4128-B1E0-1C748A382127Q42029183-A9949BC3-A4B1-4BE3-BDCE-54F6E1B8C161
P2860
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Era specific biochemical recur ...... lly localized prostate cancer.
@en
Era specific biochemical recur ...... lly localized prostate cancer.
@nl
type
label
Era specific biochemical recur ...... lly localized prostate cancer.
@en
Era specific biochemical recur ...... lly localized prostate cancer.
@nl
prefLabel
Era specific biochemical recur ...... lly localized prostate cancer.
@en
Era specific biochemical recur ...... lly localized prostate cancer.
@nl
P2093
P1476
Era specific biochemical recur ...... lly localized prostate cancer.
@en
P2093
P304
P356
10.1097/00005392-200108000-00005
P407
P577
2001-08-01T00:00:00Z